Patents by Inventor Hiroshi Tomoda

Hiroshi Tomoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060281780
    Abstract: There is provided a pest control agent comprising a compound represented by formula (I) as active ingredient.
    Type: Application
    Filed: May 31, 2006
    Publication date: December 14, 2006
    Applicants: Meiji Seika Kaisha, Ltd., The Kitasato Institute
    Inventors: Kimihiko Goto, Ryo Horikoshi, Mariko Tsuchida, Kazuhiko Oyama, Satoshi Omura, Hiroshi Tomoda, Toshiaki Sunazuka
  • Publication number: 20060252930
    Abstract: A microorganism belonging to Beauveria sp. and having ability to produce FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C (Beauveria sp. FKI-1366 FERM BP-08459) is cultured in a medium, accumulating FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C in the culture liquid and isolating FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C from the cultured mass. Since the thus obtained FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C or composition thereof have activity to enhance azole antifungal agent, the substance has an action against various fungal infections such as deep-seated mycosis and other fungal infections in the low concentration within short term. Consequently, the substance is useful for reducing frequency of appearance of resistant microorganisms and overcoming resistance, and is expected as a medicament.
    Type: Application
    Filed: August 29, 2003
    Publication date: November 9, 2006
    Inventors: Satoshi Omura, Hiroshi Tomoda, Rokura Masuma, Masayoshi Arai
  • Publication number: 20060089298
    Abstract: The present invention is comprised of culturing a microorganism having ability to produce K01-B0171-B substance and/or K01-B0171-C substance in a medium, accumulating K01-B0171-B substance and/or K01-B0171-C substance in a culture fluid and isolating K01-B0171-B substance and/or, K01-B0171-C substance from the culture fluid. The obtained K01-B0171-B substance, K01-B0171-C substance or a composition of these substances is expected to be useful as a medicament of antituberculous agent.
    Type: Application
    Filed: January 17, 2003
    Publication date: April 27, 2006
    Inventors: Satoshi Omura, Hiroshi Tomoda, Masato Iwatsuki, Yoko Takahashi
  • Publication number: 20060014825
    Abstract: The present invention relates to effective drugs for mycosis caused by so called fungi such as fungi and yeast. The present invention is comprised of culturing a microorganism belonging to genus Streptomyces and having ability to produce K99-5278A substance, K99-5278B substance and K99-5278C substance in a medium, accumulating K99-5278A substance, K99-5278B substance and K99-5278C substance in the cultured medium and isolating K99-5278A substance, K99-5278B substance and K99-5278C substance from the cultured mass. The thus obtained substances can be expected as a novel antifungal agent.
    Type: Application
    Filed: October 11, 2002
    Publication date: January 19, 2006
    Inventors: Satoshi Omura, Hiroshi Tomoda, Yoko Takahashi
  • Publication number: 20050176655
    Abstract: Macrolide derivatives having enhancing effect for activities of azole antifungal agents, acting at low concentration and within a short time against fungal infection and reducing the frequency of appearance of resistant microorganisms. One such substance is a compound represented by the formula [I]: wherein R1 is Ac, R2 and R3 are Ac, and R4 is Me; when R1 is H, R2 and R3 are Ac, and R4 is Me; when R1 is H, R2 and R3 are Ac, and R4 is H, when R1 Bzl, R2 and R3 are Bzl, and R4 is Me; when R1 is Ac, R2 and R3 are Pr, and R4 is Me; when R1 is Ac, R2 and R3 are Hex, and R4 is Me; when R1 is Ac, R2 and R3 are Bzl, and R4 is Me; when R1 is H, R2 and R3 are Pr, and R4 is Me; when R1 is H, R2 and R3 are Hex, and R4 is Me; when R1 is H, R2 and R3 are Bzl, and R4 is Me; when R1 is H, R2 is H, R3 is Bzl, and R4 is Me; when R1 is H, R2 and R3 are Hex, and R4 is H, or when R1 is H, R2 and R3 are Hex, and R4 is Et.
    Type: Application
    Filed: October 29, 2002
    Publication date: August 11, 2005
    Inventors: Satoshi Omura, Hiroshi Tomoda, Toshiaki Sunazuka, Masayoshi Arai, Tohru Nagamitsu
  • Patent number: 6902925
    Abstract: The present invention is a process for selective production of beauveriolide I substance or beauveriolide III substance, in which a beauveriolide producing microorganism strain FO-6979 or mutant thereof is cultured in a medium for fungi added with specific amino acid in order to produce beauveriolide I substance or beauveriolide III substance selectively with high yield; beauveriolide I substance or beauveriolide III substance is accumulated selectively in the cultured mass; and beauveriolide I substance or beauveriolide III substance is collected selectively with high yield from said cultured mass.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: June 7, 2005
    Assignees: Gakkou Houjin Kitasato Gakuen, Japan Society for the Promotion of Science
    Inventors: Satoshi Omura, Hiroshi Tomoda
  • Publication number: 20040265979
    Abstract: The present invention relates to a novel FKA-25 substance, which inhibits formation of the foam macrophage originated from mouse, having inhibitory action against formation of the foam macrophage and a process for production thereof. The process includes culturing Pseudobotrytis sp. FKA-25 belonging to genus Pseudobotrytis sp. and having ability to produce FKA-25 substance in a medium, accumulating FKA-25 substance in the cultured medium, and collecting FKA-25 substance from the cultured mass. The obtained FKA-25 substance specifically inhibits the formation of the foam macrophage originated from mouse and is expected to be useful for prevention and treatment of arteriosclerosis and causative diseases therefrom.
    Type: Application
    Filed: August 25, 2004
    Publication date: December 30, 2004
    Inventors: Satoshi Omura, Hiroshi Tomoda, Rokuro Masuma
  • Publication number: 20040266835
    Abstract: An electron transport system complex II inhibitor comprising 2-pyridinol derivative represented by the general formula [I] 1
    Type: Application
    Filed: August 17, 2004
    Publication date: December 30, 2004
    Inventors: Satoshi Omura, Kazuro Shiomi, Hiroshi Tomoda, Rokuro Masuma, Kiyoshi Kita
  • Patent number: 6818422
    Abstract: A microorganism capable of producing substances K97-0239 comprising K97-0239A represented by the following formula [I]: and K97-0239B represented by the following formula [II]: is cultured in a medium and the substances K97-0239 thus accumulated in the medium are collected from the culture medium. The obtained substances have a low toxicity and specifically inhibit the foaming of macrophages. Owing to these characteristics, they are useful in preventing and treating human arteriosclerosis and diseases caused thereby.
    Type: Grant
    Filed: October 1, 2003
    Date of Patent: November 16, 2004
    Assignees: Gakkou Houjin Kitasato Gakuen, Japan Society for the Promotion of Science
    Inventors: Satoshi Omura, Hiroshi Tomoda
  • Patent number: 6790968
    Abstract: A microorganism having ability to produce FKI-0076 substance represented by the following formula [I] is cultured in a medium allowing for the accumulation of FKI-0076 substance in the culture liquid. The FKI-0076 substance from can then be isolated the cultured mass. Since the substance has the ability to enhance azole antifungal agents, it provides an action against various fungal infections such as deep-seated mycosis and other fungal infections in low concentration and within a short term. Consequently, the FKI-0076 is useful for reducing the frequency of appearance of resistant microorganisms. Further, usefulness for overcoming resistance is expected.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: September 14, 2004
    Assignee: The Kitasato Institute
    Inventors: Satoshi Omura, Hiroshi Tomoda, Rokuro Masuma, Masayoshi Arai
  • Publication number: 20040157302
    Abstract: The present invention comprising culturing a microorganism which belongs to genus Streptomyces and has ability to produce K99-5041-C1x substance and/or K99-5041-C2x substance in a medium, accumulating K99-5041-C1x substance and/or K99-5041-C2x substance in the culture fluid, and isolating K99-5041-C1x substance and/or K99-5041-C2x substance form the cultured mass. Since the obtained K99-5041-C1x substance and/or K99-5041-C2x substance exhibit inhibitory activity against lanosterol synthase, these substances are expected to apply clinically for preventive and therapeutic agents caused by accumulation of cholesterol in humans and antifungal agents.
    Type: Application
    Filed: February 10, 2004
    Publication date: August 12, 2004
    Applicant: THE KITASATO INSTITUTE
    Inventors: Satoshi Omura, Hiroshi Tomoda, Yoko Takahashi, Yutaka Ebizuka, Masaaki Shibuya
  • Patent number: 6747056
    Abstract: The present invention comprising culturing a microorganism which belongs to genus Streptomyces and has ability to produce K99-5041-C1x substance and/or K99-5041-C2x substance in a medium, accumulating K99-5041-C1x substance and/or K99-5041-C2x substance in the culture fluid, and isolating K99-5041-C1x substance and/or K99-5041-C2x substance form the cultured mass. Since the obtained K99-5041-C1x substance and/or K99-5041-C2x substance exhibit inhibitory activity against lanosterol synthase, these substances are expected to apply clinically for preventive and therapeutic agents caused by accumulation of cholesterol in humans and antifungal agents.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: June 8, 2004
    Assignee: The Kitasato Institute
    Inventors: Satoshi Omura, Hiroshi Tomoda, Yoko Takahashi, Yutaka Ebizuka, Masaaki Shibuya
  • Publication number: 20040043472
    Abstract: A microorganism capable of producing substances K97-0239 comprising K97-0239A represented by the following formula [I]: and K97-0239B represented by the following formula [II]: is cultured in a medium and the substances K97-0239 thus accumulated in the medium are collected from the culture medium. The obtained substances have a low toxicity and specifically inhibit the foaming of macrophages. Owing to these characteristics, they are useful in preventing and treating human arteriosclerosis and diseases caused thereby.
    Type: Application
    Filed: October 1, 2003
    Publication date: March 4, 2004
    Inventors: Satoshi Omura, Hiroshi Tomoda
  • Publication number: 20040002533
    Abstract: The present invention comprising culturing a microorganism which belongs to genus Streptomyces and has ability to produce K99-5041-C1x substance and/or K99-5041-C2x substance in a medium, accumulating K99-5041-C1x substance and/or K99-5041-C2x substance in the culture fluid, and isolating K99-5041-C1x substance and/or K99-5041-C2x substance form the cultured mass. Since the obtained K99-5041-C1x substance and/or K99-5041-C2x substance exhibit inhibitory activity against lanosterol synthase, these substances are expected to apply clinically for preventive and therapeutic agents caused by accumulation of cholesterol in humans and antifungal agents.
    Type: Application
    Filed: February 6, 2003
    Publication date: January 1, 2004
    Inventors: Satoshi Omura, Hiroshi Tomoda, Yoko Takahashi, Yutaka Ebizuka, Masaaki Shibuya
  • Publication number: 20030195146
    Abstract: (Beauveria) sp. FO-6979 (FERM BP-6681), which belongs to the genus Beauveria and is capable of producing FO-6979-M0, -M1, -M2, -M3 and -M4 substances, is cultured in a medium to thereby accumulate the FO-6979-M0, -M1, -M2, -M3 and -M4 substances in the liquid culture medium. Then the FO-6979-M0, -M1, -M2, -M3 and -M4 substances are collected from the culture medium. The substances thus obtained are less toxic, specifically inhibit acyl-Coenzyme A: cholesterol acyltransferase, and inhibit the formation of oil droplets in macrophages. Owing to these characteristics, the above substances are useful in preventing and treating human diseases caused by cholesterol accumulation.
    Type: Application
    Filed: May 28, 2003
    Publication date: October 16, 2003
    Inventors: Satoshi Omura, Hiroshi Tomoda
  • Patent number: 6608185
    Abstract: A microorganism which belongs to the genus Gliocladium and has the ability to produce stereoisomers KF-1040T4A and KF-1040T4B which are compounds represented by the following formula [I], and stereoisomers KF-1040T5A and KF-1040T5B which are compounds represented by the following formula [II], is cultivated in a culture medium to accumulate KF-1040T4A and/or KF-1040T4B and/or KF-1040T5A and/or KF-1040T5B in the culture medium, and the substance KF-1040T4A and/or KF-1040T4B and/or KF-1040T5A and/or KF-1040T5B are harvested from the culture medium. The obtained substances are useful for the prevention and treatment of the diseases relating to arteriosclerosis, obesity, thrombosis, inflammations and immunofunctional disorders.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: August 19, 2003
    Assignee: Kitasato Institute
    Inventors: Satoshi Omura, Hiroshi Tomoda, Rokuro Masuma
  • Publication number: 20030143716
    Abstract: The present invention is a process for selective production of beauveriolide I substance or beauveriolide III substance, in which a beauveriolide producing microorganism strain FO-6979 or mutant thereof is cultured in a medium for fungi added with specific amino acid in order to produce beauveriolide I substance or beauveriolide III substance selectively with high yield; beauveriolide I substance or beauveriolide III substance is accumulated selectively in the cultured mass; and beauveriolide I substance or beauveriolide III substance is collected selectively with high yield from said cultured mass.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 31, 2003
    Inventors: Satoshi Omura, Hiroshi Tomoda
  • Patent number: 6512008
    Abstract: The present invention relates to novel substance having inhibitory action on cholesteryl ester transfer protein, WK-5344A substance and WK-5344B substance, and process for production thereof. A microorganism belonging to genus Streptomyces having ability to produce WK-5344A substance and WK-5344B substance is cultured in a medium, and the WK-5344A substance and the WK-5344B substance are accumulated in the medium, then the WK-5344A substance and the WK-5344B substance are isolated from the said medium. Since the present substance shows significant inhibitory action on cholesteryl ester transfer protein, the substance is effective for prevention and treatment of diseases caused by accumulation of cholesterol in human.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: January 28, 2003
    Assignee: Kitasato Institute
    Inventors: Satoshi Omura, Hiroshi Tomoda, Yoko Takahashi
  • Patent number: 6512099
    Abstract: Roselipin derivatives which are represented by the following formula: [wherein R1 represents a hydrogen atom, mannose or acetylated mannose, R2 represents a hydrogen atom or a methyl group, and R3 represents a methyl group or a sugar alcohol], excluding a compound in which R1 is mannose, R2 is a hydrogen atom and R3 is arabinitol (roselipin 1A or 1B) and a compound in which R1 is acetylated mannose, R2 is a hydrogen atom and R3 is arabinitol (roselipin 2A or 2B), and which are useful for preventing and treating a disease of a human which is caused by accumulation of triacylglycerol can be obtained.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: January 28, 2003
    Assignee: Kitasato Institute
    Inventors: Satoshi Omura, Hiroshi Tomoda
  • Publication number: 20020193315
    Abstract: Roselipin derivatives which are represented by the following formula: 1
    Type: Application
    Filed: March 14, 2002
    Publication date: December 19, 2002
    Inventors: Satoshi Omura, Hiroshi Tomoda